AIMS: Myocardial diastolic dysfunction (MDD) and impaired coronary flow reserve (CFR) are early signs of myocardial involvement in patients with diabetes. The important question of whether this may be reversed by glucose normalization has not been tested in a controlled clinical trial. We hypothesized that strict glycaemic control, particularly if insulin based, will improve MDD and CFR. METHODS AND RESULTS:Thirty-nine type 2 diabetes patients (mean age 61.0 +/- 7 years) with signs of diastolic dysfunction were randomly assigned to strict metabolic control by insulin (I-group; n = 21) or oral glucose lowering agents (O-group; n = 18). MDD and CFR were studied with Doppler-echocardiography including Tissue Doppler Imaging and myocardial contrast enhanced echocardiography. Fasting glucose (I-group = -2.2 +/- 2.1; O-group -1.5 +/- 0.8 mmol/L) and HbA(1c) were normalized (-0.6 +/- 0.4 and -0.7 +/- 0.4%, respectively) in both groups, but this did not significantly improve MDD in either of the groups (P = 0.65). There was no difference in CFR before and after improved glycaemic control. CONCLUSION: The hypothesis that strict glycaemic control would reverse early signs of MDD and improve CFR in patients with type 2 diabetes could not be confirmed, despite achieved normalization. Whether it is possible to influence a more pronounced diastolic dysfunction, particularly in less well-controlled diabetic patients, remains to be established.
RCT Entities:
AIMS: Myocardial diastolic dysfunction (MDD) and impaired coronary flow reserve (CFR) are early signs of myocardial involvement in patients with diabetes. The important question of whether this may be reversed by glucose normalization has not been tested in a controlled clinical trial. We hypothesized that strict glycaemic control, particularly if insulin based, will improve MDD and CFR. METHODS AND RESULTS: Thirty-nine type 2 diabetespatients (mean age 61.0 +/- 7 years) with signs of diastolic dysfunction were randomly assigned to strict metabolic control by insulin (I-group; n = 21) or oral glucose lowering agents (O-group; n = 18). MDD and CFR were studied with Doppler-echocardiography including Tissue Doppler Imaging and myocardial contrast enhanced echocardiography. Fasting glucose (I-group = -2.2 +/- 2.1; O-group -1.5 +/- 0.8 mmol/L) and HbA(1c) were normalized (-0.6 +/- 0.4 and -0.7 +/- 0.4%, respectively) in both groups, but this did not significantly improve MDD in either of the groups (P = 0.65). There was no difference in CFR before and after improved glycaemic control. CONCLUSION: The hypothesis that strict glycaemic control would reverse early signs of MDD and improve CFR in patients with type 2 diabetes could not be confirmed, despite achieved normalization. Whether it is possible to influence a more pronounced diastolic dysfunction, particularly in less well-controlled diabeticpatients, remains to be established.
Authors: Cesare Russo; Zhezhen Jin; Shunichi Homma; Tatjana Rundek; Mitchell S V Elkind; Ralph L Sacco; Marco R Di Tullio Journal: Eur J Heart Fail Date: 2010-03-07 Impact factor: 15.534
Authors: Rasa Kazlauskaite; Rami Doukky; Arthur Evans; Bosko Margeta; Arora Ruchi; Leon Fogelfeld; Russell F Kelly Journal: Diabetes Res Clin Pract Date: 2010-03-01 Impact factor: 5.602
Authors: P M Seferović; I Milinković; A D Ristić; J P Seferović Mitrović; K Lalić; A Jotić; V Kanjuh; N Lalić; B Maisch Journal: Herz Date: 2012-12 Impact factor: 1.443
Authors: Michele Senni; Walter J Paulus; Antonello Gavazzi; Alan G Fraser; Javier Díez; Scott D Solomon; Otto A Smiseth; Marco Guazzi; Carolyn S P Lam; Aldo P Maggioni; Carsten Tschöpe; Marco Metra; Scott L Hummel; Frank Edelmann; Giuseppe Ambrosio; Andrew J Stewart Coats; Gerasimos S Filippatos; Mihai Gheorghiade; Stefan D Anker; Daniel Levy; Marc A Pfeffer; Wendy Gattis Stough; Burkert M Pieske Journal: Eur Heart J Date: 2014-08-07 Impact factor: 29.983